19 BETTER DIAGNOSE AND TREAT MENTAL HEALTH DISORDERS According to the World Health Organization (WHO), 1 in 4 people are affected by mental health disorders at some point in their life. Demand for care is constantly increasing, especially for anxiety and depressive disorders, psychological trauma, behavioural disorders and addictions. In 2022, Laboratoire Cerba and Taliaz joined forces to offer physicians a new clinical test to predict the efficacy of antidepressant treatments: PREDICTIX, developed by Taliaz, uses a biological test combined with artificial intelligence to guide the care of patients with depression and orient towards the drug with the greatest chance of giving the best therapeutic outcomes from the first treatment. The solution will be available to patients in the second quarter of 2023 through the Cerba HealthCare Group routine clinical pathology network, in France and abroad. The COVID-19 epidemic highlighted the major role of the community laboratory networks in monitoring an emerging epidemic The first case of Monkeypox virus in France was diagnosed by the pathologists of Cerballiance Paris Île-de-France. Our network identified 75% of the cases diagnosed in Île-de-France and worked in conjunction with the health authorities and hospital networks to provide the best support to the patients concerned. Thanks to the samples taken by the Cerballiance teams and the tests conducted at Laboratoire Cerba, the Cerba HealthCare Group was able to offer comprehensive and appropriate outpatient care, enabling the patients to avoid a visit to the Accident and Emergency Department. Thus the role of the pathologist, which is essential in mass screening campaigns, is also important for the epidemiological monitoring of viruses by: • obtaining information on a medical/ health situation through reliable scientific data, • demonstrating its development, • informing the authorities which will decide on the measures needed to protect the population.
RkJQdWJsaXNoZXIy NzMxNTcx